TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06574412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilizumab combined with renvastinib
Description: Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \&lt;60kg, 8mg, once a day, orally, for 4 cycles Weight \&gt;60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \&lt;60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \&gt; 60kg, 12mg, once a day, orally, a total of 8 cycles.
Study: NCT06575933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral administration
Study: NCT05676463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-guided Intensity-Modulated Radiation Therapy
Description: Undergo MRI-guided IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive SOC ADT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06575075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR-HNK/Hydroxynorketamine
Description: (2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR-HNK/Hydroxynorketamine
Description: (2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Saline
Study: NCT06575946

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vestibular Hypofunction Group
Description: Demographic information form, vestibular tests, balance tests will be used in the evaluation. The demographic information form includes demographic information (name, surname, gender, smoking, alcohol use, etc.) and clinical conditions (past illnesses and/or surgeries, medications used, whether there is a history of falls, if any, frequency, whether they are afraid of heights and uncomfortable in the dark, etc.). The patients will be diagnosed with videonystagmography (VNG) after the decision of the ENT physician, and their hypofunction levels will be recorded. Vestibular and balance tests will be applied to the patients in the clinical setting. At the end of the study, it will be examined whether there is a relationship between the degree of vestibular hypofunction and the vestibular tests applied in the clinic.
Study: NCT05755204

Intervention type: DRUG
Intervention: LA-CAB
Description: Intramuscular LA-CAB for PrEP

Intervention type: DRUG
Intervention: TDF/FTC
Description: Oral TDF/FTC for PrEP
Study: NCT04577027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical travoprost 0.004% solution
Description: 30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: 30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: 30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: 30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excimer laser and travoprost
Description: 30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser and topical travoprost
Description: 30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
Study: NCT05323162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated autologous fecal microbiota transplantation
Description: Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
Study: NCT05733065

Intervention type: OTHER
Group type: OTHER
Intervention: saliva sample
Description: Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire
Description: Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
Study: NCT05526196

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: Dried flower cannabis cigarette with 22% THC

Intervention type: DRUG
Group type: OTHER
Intervention: Tobacco
Description: Dried flower cigarette with active nicotine

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis tobacco
Description: Dried flower cigarette with active nicotine and cannabis

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dried flower cigarette with both placebo tobacco and cannabis
Study: NCT04059705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Training
Description: The ThinkFIT intervention will involve two days per week participation in simultaneous cognitive and motor training activities, facilitated by the SMARTFit Multisensory FItness System.
Study: NCT05606874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-heating of flowable resin composite used as a pit and fissure sealant.
Description: The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
Study: NCT04715087

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)
Description: A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)
Description: A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application
Study: NCT04720352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: Active treatment delivers radiofrequency and cryogen

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham delivers non therapeutic levels of radiofrequency and cryogen
Study: NCT04788563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)
Description: In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original antihypertensive treatment (compulsively randomized arm)
Description: In this group, patients will maintain their original antihypertensive treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)
Description: In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
Study: NCT06503250

Intervention type: DRUG
Intervention: Atezolizumab
Description: Observational Study

Intervention type: DRUG
Intervention: Bevacizumab
Description: Observational Study

Intervention type: RADIATION
Intervention: Transarterial Chemoembolization
Description: Observational Study
Study: NCT06204328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benson relaxation technique and mHealth psychoeducation
Description: Benson relaxation technique \& mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions.
Study: NCT05962476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vibro-acoustic device
Description: Wearable device which sends low-frequency sound vibrations through the skin.
Study: NCT06554717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tesamorelin
Description: Tesamorelin SV 1.4 mg given subcutaneously daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo injection given subcutaneously daily
Study: NCT04788563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original antihypertensive treatment (voluntarily randomized arm)
Description: In this group, patients will maintain their original antihypertensive treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)
Description: In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original antihypertensive treatment (preference selection arm)
Description: In this group, patients will maintain their original antihypertensive treatment.
Study: NCT06554717

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Home-based semi-supervised exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Home-based semi-supervised exercise program
Study: NCT04468126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen
Description: Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Description: Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
Study: NCT06558786

Intervention type: OTHER
Intervention: EORTC QLQ-C30 questionnaire
Description: The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life.

Intervention type: OTHER
Intervention: QLQ-OGS25 questionnaire
Description: The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
Study: NCT06308484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Closed-loop AM-tACS
Description: Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop AM-tACS
Description: Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
Study: NCT06561672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol plus paracetamol
Description: Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and muscle relaxant (cisatracurium)
Description: propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol 2mg/kg
Study: NCT06561841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: HSK39297 tablets for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: HSK39297 tablets for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: HSK39297 tablets for 24 weeks
Study: NCT06525389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B (LAmB)
Description: Antifungal dosed at 10 mg/kg/day IV x one single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B (LAmB)
Description: Antifungal dosed at 10 mg/kg/day IV x one single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5FC)
Description: Antifungal dosed at 25mg/kg oral 3x daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5FC)
Description: Antifungal dosed at 25mg/kg oral 3x daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucytosine (5FC) placebo pill
Description: Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5FC) placebo pill
Description: Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholate Amphotericin B (DAmB)
Description: Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deoxycholate Amphotericin B (DAmB)
Description: Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
Study: NCT06562257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Honey has a long-standing reputation for promoting wound healing and offers a more economical treatment modality. Nusantara Honey, a GMP-certified product available on the market, met our criteria for quality and safety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHMB Solution
Description: PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHMB Solution
Description: PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.
Study: NCT06562309

Intervention type: OTHER
Intervention: take feces and blood samples from patients
Description: this study does not involve any intervention

Intervention type: OTHER
Intervention: take feces and blood samples from patients
Description: this study does not involve any intervention
Study: NCT05685498

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer-led HIV self-testing among male fisherfolk in Uganda
Description: This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
Study: NCT06424457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video assisted thoracoscopy (VATS)
Description: the investigators compare the outcomes of intervention by VATS and doing complete decortication or open surgery thoracotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open thoracotomy
Description: the investigators assess the outcomes of intervention by doing complete decortication through open surgery thoracotomy